Matthew M Hsieh
Overview
Explore the profile of Matthew M Hsieh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1986
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lawal R, Mukherjee D, Limerick E, Coles W, Hsieh M, Dillon L, et al.
Blood
. 2022 Aug;
140(23):2514-2518.
PMID: 36044658
No abstract available.
12.
Malech H, Garabedian E, Hsieh M
Hematol Oncol Clin North Am
. 2022 Jun;
36(4):627-645.
PMID: 35773053
The earliest conceptual history of gene therapy began with the recognition of DNA as the transforming substance capable of changing the phenotypic character of a bacterium and then as the...
13.
Sharma A, Leonard A, West K, Gossett J, Uchida N, Panch S, et al.
Br J Haematol
. 2022 Jun;
198(4):740-744.
PMID: 35737751
We adjusted haematopoietic stem and progenitor cell (HSPC) apheresis collection from patients with sickle cell disease (SCD) by targeting deep buffy coat collection using medium or low collection preference (CP),...
14.
Nickel R, Maher J, Hsieh M, Davis M, Hsieh M, Pecker L
J Clin Med
. 2022 May;
11(9).
PMID: 35566443
Curative therapy for sickle cell disease (SCD) currently requires gonadotoxic conditioning that can impair future fertility. Fertility outcomes after curative therapy are likely affected by pre-transplant ovarian reserve or semen...
15.
Lew J, Fitzhugh C, Tisdale J, Hsieh M
Transplant Cell Ther
. 2021 Aug;
27(12):1019.e1-1019.e4.
PMID: 34419651
Hematopoietic cell transplantation (HCT) offers long-term cure against early morbidity and mortality of hemoglobinopathies, such as sickle cell disease (SCD) and beta-thalassemia. Following HCT, sirolimus is an immunosuppressant used to...
16.
Alzahrani M, Damlaj M, Jeffries N, Alahmari B, Singh A, Rondelli D, et al.
Br J Haematol
. 2021 Feb;
192(4):761-768.
PMID: 33534948
Non-myeloablative haematopoietic progenitor cell transplantation (HPCT) from matched related donors (MRD) has been increasingly utilized in sickle cell disease (SCD). A total of 122 patients received 300 cGy of total...
17.
Mayer B, Nemeth K, Krepuska M, Myneni V, Maric D, Tisdale J, et al.
Clin Endocrinol (Oxf)
. 2020 Dec;
94(5):888-890.
PMID: 33314284
No abstract available.
18.
Oldham M, Conrey A, Pittman C, Fisher C, Hargrett S, West K, et al.
J Clin Pharmacol
. 2020 Jul;
61(1):41-51.
PMID: 32673439
Adults with sickle cell disease (SCD) experience acute and chronic complications and die prematurely. When taken at maximum tolerated dose (MTD), hydroxyurea prolongs survival; however, it has not consistently reversed...
19.
Nickel R, Flegel W, Adams S, Hendrickson J, Liang H, Tisdale J, et al.
EClinicalMedicine
. 2020 Jul;
24:100432.
PMID: 32637902
Background: Hematopoietic stem cell transplantation (HSCT) is curative for patients with sickle cell disease (SCD). Prior to HSCT, patients with SCD commonly receive RBC transfusions with some becoming RBC or...
20.
Hsieh M, Bonner M, Pierciey F, Uchida N, Rottman J, Demopoulos L, et al.
Blood Adv
. 2020 May;
4(9):2058-2063.
PMID: 32396618
No abstract available.